# A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

> **NCT05894928** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 21 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LOXO-783
- **DRUG:** Cholestyramine

## Key facts

- **NCT ID:** NCT05894928
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-07
- **Primary completion:** 2023-07-09
- **Final completion:** 2023-07-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05894928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05894928, "A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05894928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*